-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $56

Benzinga·12/09/2025 16:46:41
Listen to the news
Barclays analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Overweight and raises the price target from $36 to $56.